Home  /   Products  /   Cardiovascular  /   Lappaconitine hydrobromide (Allapinin) 25 mg – [30 tablets]

Lappaconitine hydrobromide (Allapinin) 25 mg – [30 tablets]


Antiarrhythmic drugs

SKU: 60925 Category:


Allapinin Pharmacodynamics
Allapinin® is a bromine hydrogen bromide salt of lappaconitin alkaloid with associated alkaloids, derived from the herb of white wolfberry – Aconitum leucostomum Worosch. and rhizomes with roots of northern wolfberry (tall wolfberry) Aconitum septentrionale Koelle (A. excelsum Reichenb.), family Ranunculaceae.
Antiarrhythmic drug of IC class.
Blocks “fast” sodium channels of cardiomyocyte membranes. It inhibits atrioventricular (AV) and intraventricular conduction, shortens effective and functional refractory periods of atria, AV node, Gis bundle and Purkinje fibers, does not affect QT interval duration, conduction along AV node in anterograde direction, heart rate (HR) and blood pressure, myocardial contractility (in initial absence of heart failure phenomena). It does not inhibit sinus node automatism, has no negative inotropic effect, has no antihypertensive and m-cholinolytic effects.
It has moderate antispasmodic, coronary dilator, local anesthetic and sedative effect.
When taken orally, the effect develops in 40-60 minutes, reaches a maximum in 4-5 hours and lasts for 8 hours or more.

Ventricular and ventricular extrasystoles, paroxysmal atrial fibrillation and flutter; paroxysmal supraventricular tachycardia, including in Wolf-Parkinson-White syndrome (WPW), paroxysmal ventricular tachycardia (in the absence of myocardial organic changes).

Hypersensitivity to the drug, sinoatrial block, AV block of II and III degree (without artificial pacemaker), cardiogenic shock, right bundle branch block combined with left bundle branch block, severe arterial hypotension (systolic BP less than 90 mm Hg), moderate and severe congestive heart failure. ), moderate and severe chronic heart failure III-IV functional class according to NYHA classification, severe left ventricular myocardial hypertrophy (≥1.4 cm), presence of postinfarction cardiosclerosis, severe liver function and/or renal impairment, age under 18 years (effectiveness and safety are not established), fructose intolerance and glucose/galactose malabsorption or sucrose/isomaltase deficiency (drug contains sucrose).
Use with caution in degree I AV blockade, intraventricular conduction disorders, sinus node weakness syndrome (SSNS), bradycardia, marked severe peripheral circulation disorders, closed-angle glaucoma, Benign prostatic hypertrophy, Purkinje fibers conduction disorders, Gis bundle one leg block, electrolyte and water metabolism disorders (hypokalemia, hyperkalemia, hypomagnesemia), simultaneous use of other antiarrhythmic agents
Pregnancy and lactation:
Administration of Allapinin® drug in pregnancy is not recommended. It is possible to use the drug only for vital indications, if the estimated benefit to the mother exceeds the potential risk to the fetus/fetus.
There are no data on excretion of lappaconitine hydrobromide into the breast milk. It is not recommended to use the drug during breastfeeding. If application of the drug during lactation is necessary, breastfeeding should be stopped.

Dosage and administration

  • Orally, after a meal with a small amount of water at room temperature, do not crush.
    Take 1 tablet (25 mg) every 8 hours, every 6 hours if there is no therapeutic effect.
    It is possible to increase a single dose to 2 tablets (50 mg) every 6-8 hours. The maximum daily dose is 300 mg (12 tablets).
  • Duration of treatment and correction of the dosage regimen (dose increase) is determined by the physician.